Horizon, AstraZeneca Collaborate on Genotypes for Synthetic Lethality | GenomeWeb

NEW YORK (GenomeWeb News) – Horizon Discovery today announced a research collaboration and licensing deal with AstraZeneca to interrogate oncology-relevant genotypes in order to identify and validate new drug targets.

Horizon will query a defined set of genotypes for synthetic lethality and carry out in vitro screening using the company's siRNA platform, as part of the agreement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

This Week in Science: New research into the emergence of infectious diseases, and scientists report on proteins involved in melanoma.

The hashtag #stupidcommonnames is gaining fans among scientists who find the common names of some animals and plants dumb.

Fed up with budget slashes, job cuts, and muzzling mandates, researchers in Canada are making science a campaign issue in the upcoming elections.

A former NIH program officer says the Internet has blasted open the door for scientific publications more interested in dollars than quality research.

Sep
10
Sponsored by
Qiagen

In this online seminar, Jo Vandesompele of the Center for Medical Genetics at Ghent University will discuss methods for improving the analysis of microRNA expression from a range of samples.